<DOC>
	<DOCNO>NCT00942084</DOCNO>
	<brief_summary>Acyclovir drug use treat herpes simplex virus ( HSV ) infection baby . Appropriate dose acyclovir know adult child acyclovir adequately study full-term premature neonate . HSV serious infection baby &lt; 6 month age often result death profound mental retardation . HSV lead profound mental retardation young infant virus attack central nervous system . The investigator hypothesize currently recommend dose acyclovir inadequate produce adequate blood level combat herpes simplex infection . The investigator propose study acyclovir level blood baby place acyclovir treat suspect HSV infection . This allow determine appropriate dose premature infant . This unmet public health need likely drug behaves differently premature infant term infant old child . Premature baby body water less body tissue . Their kidney immature function well full term infant . Premature neonates also great risk herpes infection poorly functioning immature immune system . Early appropriate treatment acyclovir result improved outcome term infant .</brief_summary>
	<brief_title>A Study Describe Pharmacokinetics Acyclovir Premature Infants ( PTN_Acyclo )</brief_title>
	<detailed_description>Neonatal herpes infection carry major risk death untreated . Prognosis related disease extent time therapy , make early diagnosis crucial . Mortality pre-antiviral era 90 % disseminated disease 50 % central nervous system ( CNS ) disease . Institution high-dose ( 60 mg/kg/day ) antiviral therapy acyclovir reduce mortality 31 % disseminated disease 6 % CNS disease.1 Although acyclovir reduce mortality dramatically , morbidity remain high . Study population : Infants &lt; 45 day postnatal age , suspect systemic infection divide group gestational postnatal age : Group-1 : 23-29 week gestational age , &lt; 14 day postnatal age Group-2 : 23-29 week gestational age , 14-44 day postnatal age Group-3 : 30-34 week gestational age , &lt; 45 day postnatal age Intravenous acyclovir administer 3 day . Timing PK sample collection respect end IV infusion . Timed PK sample drawn dose 1 , dose 5 , 6 , 7 , 8 , 9 . Dose 1 : 0-15 minute completion 1st dose ; Within 30 minute prior administration 2nd dose Steady state [ dose 5 6 ( group 1 2 ) , dose 8 9 ( group 3 ) ] : Within 30 minute prior dose ; 0-15 minute completion dose ; 2-3 hour completion dose ; Within 30 minute prior administration next dose Last dose : 6-7 hour last dose ( group 1 2 ) 10-11 hour last dose ( group 3 )</detailed_description>
	<mesh_term>Premature Birth</mesh_term>
	<mesh_term>Sepsis</mesh_term>
	<mesh_term>Herpes Simplex</mesh_term>
	<mesh_term>Acyclovir</mesh_term>
	<criteria>The investigator study site personnel document source document ( e.g. , hospital chart ) inform consent obtain . Laboratory test nonpharmacologic treatment procedure perform standard care within 72 hour prior first dose study drug may use screening procedure record CRF . Inclusion Criteria 1 . &lt; 45 day age time initial study drug administration . 2 . Sufficient venous access permit administration study medication . 3 . Availability willingness parent/legal guardian provide write informed consent . 4 . Suspected HSV sepsis OR At least two ( 2 ) follow Signs sepsis AND negative blood culture &gt; 24 hours7 Respiratory distress8 Lethargy8 Fever ≥ 38.0°C7 Skin lesions7,8 Seizures ( clinical OR EEG confirm ) 7 Irritability7 AST OR ALT &gt; 2 X upper limit normal7,8 &gt; 20 WBCs/µL &gt; 500 RBCs/µL7 Exclusion Criteria 1 . History anaphylaxis attribute acyclovir . 2 . Serum creatinine &gt; 1.7 mg/dL . 3 . Urine output &lt; 0.5 mL/kg/hour previous 12 hour 4 . Previous participation study . 5 . Concomitant condition , opinion investigator would preclude participant 's participation study</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>45 Days</maximum_age>
	<verification_date>November 2013</verification_date>
	<keyword>HSV</keyword>
	<keyword>Acyclovir</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Neonate</keyword>
	<keyword>Premature</keyword>
	<keyword>Sepsis</keyword>
</DOC>